Principal Securities, Inc. Verona Pharma PLC Transaction History
Principal Securities, Inc.
- $4.47 Trillion
- Q1 2025
A detailed history of Principal Securities, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Principal Securities, Inc. holds 40 shares of VRNA stock, worth $4,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 40
-0.0%
Holding current value
$4,212
Previous $1.86 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
295Shares Held
73.9MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$691 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$581 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$413 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$364 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$305 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.42B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...